Global Perfluorodecalin for Ophthalmic Surgery Market Strategic Research Report

Scope of the Report

The global Perfluorodecalin for Ophthalmic Surgery market size is predicted to grow from US$ 38.05 million in 2025 to US$ 56.48 million in 2032; it is expected to grow at a CAGR of 5.9% from 2026 to 2032.

In 2025, global Perfluorodecalin for Ophthalmic Surgery production reached approximately 270 k units, with an average global market price of around US$144 per unit. Perfluorodecalin for ophthalmic surgery is a perfluorocarbon aromatic organic compound. At room temperature, it is a colorless, odorless, non-toxic liquid with a low boiling point and a high boiling point. It can be used to fix and protect the eyeball during ophthalmic surgery.

According to the 2022 White Paper on Chronic Disease Management of Common Ocular Fundus Diseases in China issued by the National Clinical Research Center for Ocular Diseases, the prevalence of fundus diseases reaches 21.4% among those aged 60 and above and rises to 25.6% among those over 70. The rising caseload of rhegmatogenous retinal detachment requiring vitrectomy sustains stable clinical usage of perfluorodecalin as a temporary intraoperative tamponade agent. Perfluorodecalin represents the longest-established product within the ophthalmic heavy liquid category, with product standards already filed with and approved by the NMPA. However, as a first-generation perfluorocarbon liquid, its clinical limitations center on postoperative residual concerns tied to purity. Comparative studies of different commercial brands have detected significant variability in hydrogenated impurity levels across batches, with 1H-PFO concentrations ranging from below 1 ppm to 376 ppm, directly affecting postoperative inflammatory risk control. Breakthroughs in purification technology are becoming the critical threshold for maintaining competitiveness in the high-end segment. From a regulatory standpoint, perfluorodecalin is classified as a Class III high-risk medical device across major markets, subject to rigorous premarket approval. China‘s NMPA mandates purity of no less than 95% as a fundamental registration criterion. The EU REACH restriction proposal on PFAS has placed fluorocarbon compounds including perfluorodecalin under review, progressively raising compliance costs. In China, provincial volume-based procurement initiatives have included ophthalmic heavy liquids within price linkage mechanisms, typically capping bid prices at national historical lows while preserving hospitals’ discretionary allocation rights beyond contracted volumes. Upstream fluorocarbon raw material production capacity is being scaled domestically, with local manufacturers having already obtained Class III medical device registration certificates for perfluorodecalin, steadily enhancing supply chain autonomy. The market will continue to evolve along two principal trajectories: purification technology upgrades and regional supply-side structural substitution, with higher clinical purity requirements serving as the decisive variable in product differentiation.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Perfluorodecalin for Ophthalmic Surgery market?

What factors are driving Perfluorodecalin for Ophthalmic Surgery market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Perfluorodecalin for Ophthalmic Surgery market opportunities vary by end market size?

How does Perfluorodecalin for Ophthalmic Surgery break out by Type, by Application?

This report presents a comprehensive overview of the global Perfluorodecalin for Ophthalmic Surgery market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Purity ≥ 95%
• Purity ≥ 97%

Segment by Specification

• 5 ml/unit
• 7 ml/unit

Segment by Package

• Sterile Vials
• Pre-filled Syringes

Segment by Application

• Hospital
• Ophthalmology Clinic

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Perfluorodecalin for Ophthalmic Surgery market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital, Ophthalmology Clinic evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact